Close Menu

Personalis

The ACE ImmunoID test uses exome and transcriptome sequencing to identify neoantigens for the development of personalized cancer vaccines.

The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.

The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.

Researchers compared three open source annotation tools, and also looked at correspondence with public databases, identifying a number of stumbling blocks.

The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.

The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.

The companies have signed a letter of intent to offer Personalis' next-generation tumor sequencing and interpretation technology to customers in Canada.

The partners will provide comprehensive clinical genomic testing for tumor profiling and inherited genetic disease at LSU Health New Orleans' Precision Medicine Program.

Compared to commercial exome kits and whole-genome sequencing, the firm's test had improved coverage in medically interpretable genes and the 56 ACMG genes.

Pages

The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.

A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.

Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.

In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.